EIPICO Pharmaceuticals, Egypt’s leading pharmaceutical exporter, announced consolidated results for the first half of 2025, recording a net profit of EGP 828 million, a 6% increase compared with the same period last year.
Dr. Ahmed Kelani, Chairman and Managing Director of EIPICO, emphasized that the company has successfully met all its performance targets during the six-month period from January 1 to June 30, 2025.
According to the company’s financial disclosures, net sales reached EGP 4.61 billion, representing a 36% year-on-year growth. Export revenues climbed to EGP 1.521 billion, marking a 27.5% increase, further consolidating EIPICO’s position as Egypt’s number one pharmaceutical exporter, contributing 26% of Egypt’s total pharmaceutical exports to 65 international markets.
During the same reporting period, production volume surged to EGP 5.043 billion, reflecting a 56% growth rate, with output amounting to 159.63 million packages, up 8% year-on-year. Dr. Kelani noted that this performance underlines the company’s ability to balance domestic supply with expanding export demand.
Citing IQVIA Foundation’s latest report on the Egyptian pharmaceutical market, Dr. Kelani highlighted that EIPICO ranks second among all pharmaceutical companies in unit sales, capturing a 6.4% market share. Eight of EIPICO’s products are listed among the top 100 best-selling medicines in Egypt by unit volume.
In terms of sales value, EIPICO claimed the seventh position in the pharmacy market, supported by a 41% growth rate, demonstrating the company’s resilience and competitiveness in a challenging market environment.
Concluding his remarks, Dr. Kelani affirmed EIPICO’s commitment to reinforcing its leadership in Egypt’s pharmaceutical sector while expanding its global footprint. “Our performance in the first half of 2025 reflects both operational strength and strategic vision. We remain focused on enhancing our portfolio, meeting market needs, and sustaining our role as Egypt’s foremost pharmaceutical exporter,” he stated.
